FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema Following Branch Retinal Vein Occlusion
• Macular Edema Following Central Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

SUPPL AP for EYLEA (AFLIBERCEPT)